Ics, Corrosion Inhibitors products Informatics and Intelligent Systems, Healthcare University of Vienna, Vienna, Austria. Received: 23 December 2015 Accepted: 23 FebruaryReferences 1. Palumbo A, Anderson K. A number of myeloma. N Engl J Med. 2011;364:1046?0. 2. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in numerous myeloma: changes in early mortality and outcomes in older sufferers. Leukemia. 2014;28:1122?. 3. Cao L, Bombard J, Cintron K, Sheedy J, Weetall ML, Davis TW. BMI1 as a novel target for drug discovery in cancer. J Cell Biochem. 2011;112:2729?1. four. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 1991;65:753?three. 5. Haupt Y, Bath ML, Harris AW, Adams JM. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene. 1993;eight:3161?. 6. Brunk BP, Martin EC, Adler PN. Drosophila genes posterior sex combs and suppressor two of zeste encode proteins with homology for the murine bmi-1 oncogene. Nature. 1991;353:351?. 7. Hern dez-Mu z I, Taghavi P, Kuijl C, Neefjes J, van Lohuizen M. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/ EZH2 as well as the maintenance DNA methyltransferase DNMT1. Mol Cell Biol. 2005;25:11047?8. 8. Cao R, Tsukada Y-I, Zhang Y. Function of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell. 2005;20:845?4. 9. Song L-B, Zeng M-S, Liao W-T, Zhang L, Mo H-Y, Liu W-L, et al. Bmi-1 is usually a novel (S,R)-Noscapine (hydrochloride) In Vitro molecular marker of nasopharyngeal carcinoma progression and immortalizes main human nasopharyngeal epithelial cells. Cancer Res. 2006;66:6225?two. ten. Wang H, Pan K, Zhang H, Weng D, Zhou J, Li J, et al. Improved polycombgroup oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:535?1. 11. Tong Y-Q, Liu B, Zheng H-Y, He Y-J, Gu J, Li F, et al. Overexpression of BMI-1 is linked to poor prognosis in cervical cancer. Asia Pac J Clin Oncol. 2012;8:e55?2. 12. Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, et al. Bmi-1 is valuable as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood. 2006;107:305?.13. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A. Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in individuals with acute myeloid leukemia. Leukemia. 2007;21:1116?two. 14. Teshima K, Nara M, Watanabe A, Ito M, Ikeda S, Hatano Y, et al. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential inside the side population of refractory mantle cell lymphoma. Oncogene. 2014;33:2191?03. 15. Yuan J, Takeuchi M, Negishi M, Oguro H, Ichikawa H, Iwama A. Bmi1 is crucial for leukemic reprogramming of myeloid progenitor cells. Leukemia. 2011;25: 1335?3. 16. Yadirgi G, Leinster V, Acquati S, Bhagat H, Shakhova O, Marino S. Conditional activation of Bmi1 expression regulates self-renewal, apoptosis, and differentiation of neural stem/progenitor cells in vitro and in vivo. Stem Cells. 2011;29:700?two. 17. Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y, et al. The polycomb gene solution BMI1 contributes for the upkeep of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 2008;68:7742?. 18. De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, et al. Comparison of gene expression profil.